New research is being presented at ICAAC 2014, the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, from September 5 to 9 in Washington, DC.
Meeting Highlights
Big Benefits With Antibiotic Stewardship Programs
Finding Antibiotic-Resistant Bacteria
Clinical Education Key to Procalcitonin Testing
Trends in P. aeruginosa Septicemia
Recurrent CDI: A Look at Outcomes
News From ICAAC 2014
Coinfection less likely among children with pneumonia serotypes
Ebola Response: Slowed by a ‘Perfect Storm’ of Setbacks
Researchers propose new strategies to combat antimicrobial resistance
In-house PCR had greater sensitivity than commercial test kits for detecting intestinal protozoa
Hospitalization rates increased for patients with HCV, diabetes
Antimicrobial dosing adjusted for weight led to cost savings
Lab-developed, commercial assays performed comparably in norovirus detection
Clinical outcomes did not differ between children with, without C. difficile
Swiss MSM had vague awareness of HCV treatments, modes of transmission
Antifungal’s Lower Side Effects Hold Promise
Depression Linked to Postop Infection
Diabetic Foot Infections Fall — Not!
Moxifloxacin Struggles Against Current TB Drugs: REMox Trial
Quadruple Dosing of Doripenem Safe in Patients With CF
Early targeted antibiotics improved outcomes in S. aureus bloodstream infections
SAPPHIRE-I, II trials demonstrate minimal serious AE in HCV
Vancomycin May Protect Against C. Diff Recurrence
One Dose of Flu Drug Shortens Fever
Single-step NAAT algorithm improved C. difficile detection
Efficacy of triple therapy varied among Israeli patients with HCV
Peramivir safe, effective in treating influenza symptoms
More From ICAAC 2014
Cubist ICAAC Award and Lecture
Walter E. Washington Convention Center
